Join        Login             Stock Quote

C.R. Bard (BCR) 4Q Earnings Increase 13 Pct, Beat Estimates

 January 31, 2013 04:22 PM

(By Balaseshan) C.R. Bard Inc. (NYSE: BCR), a maker of medical devices, reported a 13% increase in quarterly earnings on strong performance across three of its four product groups. Results exceeded Wall Street expectations.

Earnings for the fourth quarter were $128.2 million or $1.52 per share, higher than last year's $113.8 million or $1.30 per share. Adjusted earnings per share were $1.70 per share, unchanged from last year.

Sales rose 1% to $762.6 million. Excluding the impact of foreign exchange, sales for the latest quarter increased 2%.

Analysts, on average, polled by Thomson Reuters had expected BCR to earn $1.67 per share on revenue of $757.49 million for the fourth quarter.

[Related -C.R. Bard (BCR) Initiated at 'Hold' by Brean Capital]

Vascular sales fell 4%, while urology sales rose 3%. Oncology sales increased 5%, while sales from surgical specialties rose 4%.

Sales in the U.S. decreased 1% to $498.1 million, while sales outside the U.S. increased 6% to $264.5 million. Excluding the impact of foreign exchange, sales outside the U.S. grew 8% over the prior-year period.

"While the near term environment remains challenging, especially in our developed markets, we are executing a strategy to return to faster growth through investments in emerging markets and new product categories," said Timothy Ring, chairman and chief executive officer.

BCR closed Thursday's regular session down 0.16% at $102.07. The stock has been trading between $91.41 and $108.31 for the past 52 weeks.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageUS REITs Edged Higher Last Week As Emerging Markets Slumped

Real estate investment trusts (REITs) in the US took the lead in last week’s shortened holiday trading week read on...

article imageA Contrarian Perspective On The Short EuroTtrade

As the euro continues to drift lower, it has become the accepted wisdom that we are headed for parity with read on...

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.